ADVFN US – Market Content Editor

The investment gives Buzbuzian Capital exposure to Getchell Gold’s Fondaway Canyon project, which has a preliminary economic assessment outlining a US$1 billion pre-tax net present value and projected annual gold production of 150,000 ounces. Key Investor Takeaways Why GGLDF Stock Is in Focus Getchell Gold has secured a $300,000 investment from Canadian family office Buzbuzian…

China SXT Pharmaceuticals has agreed to sell 8 million shares at $1.50 each, alongside warrants containing a zero-cash exercise provision and an additional $12 million purchase option for institutional investors. Key Investor Takeaways Why SXTC Stock Is in Focus China SXT Pharmaceuticals has entered into a definitive securities purchase agreement with institutional investors for a…

DarkIris has announced a $6 million financing to support working capital and corporate operations, with a warrant structure that could substantially increase its outstanding share count. Key Investor Takeaways Why DKI Stock Is in Focus DarkIris has priced a best-efforts public offering expected to generate approximately $6 million in gross proceeds before placement agent fees…

Medicus Pharma is prioritizing clinical milestones, regulatory progress and potential partnerships across its oncology, dermatology and urology portfolio as it seeks to demonstrate returns on three years of investment. Key Investor Takeaways Why MDCX Stock Is in Focus Medicus Pharma has provided a three-year shareholder update detailing its transition from a company primarily focused on…

The financing will provide additional working capital for Sunshine Biopharma, but the inclusion of two warrants per unit creates potential future share dilution for existing shareholders. Key Investor Takeaways Why SBFM Stock Is in Focus Sunshine Biopharma has announced the pricing of a public offering expected to generate approximately $6 million in gross proceeds through…

Femasys will present its fertility treatment and diagnostic portfolio at the ASRM 2026 Scientific Congress & Expo, highlighting its efforts to expand adoption across OB/GYN practices and reproductive endocrinology clinics. Key Investor Takeaways Why FEMY Stock Is in Focus Femasys has confirmed its participation in the American Society for Reproductive Medicine’s 2026 Scientific Congress &…

The $36.50-per-share cash acquisition adds two established pain treatments to Viatris’ portfolio and is expected to contribute immediately to its financial guidance metrics following completion by the end of 2026. Key Investor Takeaways Why VTRS and PCRX Stocks Are in Focus Viatris has entered into a definitive agreement to purchase all outstanding shares of Pacira…

argenx’s experimental CD122 inhibitor met its primary endpoint in a 126-patient study, demonstrating protection against gluten-induced intestinal damage and supporting advancement into late-stage clinical development. Key Investor Takeaways Why ARGX Stock Is in Focus argenx has reported positive topline results from its randomized, double-blind, placebo-controlled Phase 2 FB102-301 study evaluating FB102 in adults with celiac…

The Japanese Patent Office has signalled its intention to grant patent protection for bioAffinity Technologies’ noninvasive lung cancer detection technology, expanding the company’s intellectual property coverage in Asia. Key Investor Takeaways Why BIAF Stock Is in Focus bioAffinity Technologies has received a Notice of Allowance from the Japan Patent Office for its patent application titled…

FingerMotion is seeking long-term capacity agreements for Brooks Campus #1, with powered land expected to become available in early 2027 as the company advances its broader 99 MW computing infrastructure program. Key Investor Takeaways Why FNGR Stock Is in Focus FingerMotion has initiated commercial discussions for Brooks Campus #1, a planned 9.9 megawatt behind-the-meter power…